A. Grauer

发表

Underdiagnosis of Vertebral Fractures Is a Worldwide Problem: The IMPACT Study

H. Genant, R. Eastell, P. Delmas, 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effects of 17β‐estradiol on calcitonin secretion and content in a human medullary thyroid carcinoma cell line

A. Grauer, R. Ziegler, F. Raue, 1991 .

Diagnostic Value of the Peptides from the Calcitonin Gene

A. Grauer, F. Raue, H. Schneider, 1990 .

Seasonal variation of biochemical indexes of bone turnover: results of a population-based study.

A. Grauer, M. Seibel, R. Ziegler, 1998, The Journal of clinical endocrinology and metabolism.

Change in Bone Density and Reduction in Fracture Risk: A Meta‐Regression of Published Trials

J. Cauley, M. Bouxsein, D. Bauer, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab

A. Grauer, N. Lane, Toshio Matsumoto, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis

A. Bower, A. Grauer, M. Bonafede, 2015, Osteoporosis International.

Fracture risk remains reduced one year after discontinuation of risedronate

N. Watts, A. Grauer, A. Chines, 2008, Osteoporosis International.

C. McCulloch, E. Vittinghoff, J. Cauley, 2020, The lancet. Diabetes & endocrinology.

In vitro detection of neutralizing antibodies after treatment of paget's disease of bone with nasal salmon calcitonin

A. Grauer, R. Ziegler, F. Raue, 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

A Survey of Women's Awareness of and Reasons for Lack of Postfracture Osteoporotic Care

A. Grauer, D. Boudreau, D. Scholes, 2017, Journal of the American Geriatrics Society.

Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis

S. Silverman, M. Nevitt, D. Revicki, 2015, Osteoporosis International.

Relationship Between Pretreatment Bone Resorption and Vertebral Fracture Incidence in Postmenopausal Osteoporotic Women Treated With Risedronate

V. Naganathan, A. Grauer, M. Seibel, 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Association between transitory increase in PTH following denosumab administration and reduced intracortical porosity is a distinctive attribute of denosumab therapy

A. Grauer, J. Bilezikian, J. Zanchetta, 2012 .

Romosozumab in postmenopausal women with osteopenia.

A. Grauer, M. McClung, 2014, The New England journal of medicine.

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab

Jacques P. Brown, A. Grauer, M. McClung, 2020, Osteoporosis International.

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

Jacques P. Brown, Lei Zhou, N. Watts, 2011, Osteoporosis International.

Reply to: Change in Bone Density and Reduction in Fracture Risk: A Meta‐Regression of Published Trials

J. Cauley, M. Bouxsein, D. Bauer, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Formation of neutralizing antibodies after treatment with human calcitonin.

A. Grauer, R. Ziegler, F. Raue, 1993, The American journal of medicine.

Bisphosphonate therapy for skeletal metastases

A. Grauer, R. Ziegler, 1998, Der Orthopäde.

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double‐Blind, Phase 2, Parallel Group Study

Jacques P. Brown, A. Díez-Pérez, A. Grauer, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Jacques P. Brown, H. Genant, A. Grauer, 2017, The Lancet.

Differential effects of 1,25-dihydroxyvitamin D3 on cell proliferation and calcitonin gene expression.

A. Grauer, R. Ziegler, F. Raue, 1994, Endocrinology.

Neuron-specific enolase in medullary thyroid carcinoma: immunohistochemical demonstration, but no significance as serum tumor marker

A. Grauer, R. Ziegler, F. Raue, 2004, Journal of Cancer Research and Clinical Oncology.

Evaluation of somatostatin as a plasma tumor marker in medullary thyroid carcinoma.

A. Grauer, R. Ziegler, F. Raue, 1995, Thyroid : official journal of the American Thyroid Association.

CHAPTER 47 – Paget's Disease of Bone

A. Grauer, E. Siris, S. Ralston, 2006 .

Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone.

A. Grauer, M. Seibel, R. Ziegler, 2000, Clinical chemistry.

Differential induction of proto-oncogene expression and cell death in ocular tissues following ultraviolet irradiation of the rat eye

A. Grauer, M. Zimmermann, F. Gillardon, 1999, The British journal of ophthalmology.

A case of neuroendocrine oncogenic osteomalacia associated with a PHEX and fibroblast growth factor-23 expressing sinusidal malignant schwannoma.

A. Grauer, R. Ziegler, H. Wickert, 2001, Bone.

Hypercalcemia associated with hematologic malignancies.

A. Grauer, 1994, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.

A. Grauer, K. Saag, J. Petersen, 2018, The New England journal of medicine.

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

A. Grauer, R. Dinavahi, C. Libanati, 2019, Osteoporosis International.

Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin.

A. Grauer, R. Ziegler, F. Raue, 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

Multiple endocrine neoplasia type 2. Clinical features and screening.

A. Grauer, F. Raue, K. Frank‐Raue, 1994, Endocrinology and metabolism clinics of North America.

Romosozumab for the treatment of postmenopausal osteoporosis

A. Grauer, F. Cosman, D. Crittenden, 2021, Marcus and Feldman's Osteoporosis.

Regulation of calcitonin gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat

A. Grauer, J. Silver, T. Naveh-Many, 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

OP0248 Inhibition of Sclerostin with Romosozumab in Postmenopausal Women with Low Bone Mineral Density: Phase 2 Trial Results

Jacques P. Brown, S. Boonen, A. Díez-Pérez, 2013 .

1,25-Dihydroxyvitamin D3 suppresses dexamethasone effects on calcitonin secretion

A. Grauer, R. Ziegler, F. Raue, 1990, Molecular and Cellular Endocrinology.

Blue Sclerae in Osteogenesis Imperfecta

A. Grauer, G. Leidig-Bruckner, 1998 .

PDN-21 (katacalcin) and chromogranin A: tumor markers for medullary thyroid carcinoma.

A. Grauer, F. Raue, E. Blind, 1992, Henry Ford Hospital medical journal.

A new in vitro bioassay for human calcitonin: validation and comparison to the rat hypocalcemia bioassay.

A. Grauer, R. Ziegler, F. Raue, 1992, Bone and mineral.

In vitro-Bioassays für humanes Calcitonin

A. Grauer, F. Raue, E. Blind, 1993 .

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

A. Grauer, I. C. Tudor, P. Munster, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.

Richard Eastell, Christian Roux, R. Eastell, 2007, The Journal of clinical endocrinology and metabolism.

A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures

M. Bhandari, A. Grauer, T. Miclau, 2020, The Journal of bone and joint surgery. American volume.

A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.

J. Reginster, S. Boonen, A. Grauer, 2012, The Journal of clinical endocrinology and metabolism.

Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.

S. Cummings, O. Tørring, S. Boonen, 2011, The Journal of clinical endocrinology and metabolism.

Denosumab for the Management of Postmenopausal Osteoporosis

A. Grauer, A. Singer, 2010, Postgraduate medicine.

Risk of subsequent fracture after prior fracture among older women

A. Grauer, J. Curtis, D. Wenkert, 2018, Osteoporosis International.

Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

A. Grauer, L. Hofbauer, E. Lau, 2016, The New England journal of medicine.

Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.

A. Grauer, C. Libanati, A. Miyauchi, 2017, Bone.

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

A. Grauer, M. Brandi, M. Lorentzon, 2017, The New England journal of medicine.

Romosozumab in postmenopausal women with low bone mineral density

Cesar Libanati, Steven Boonen, Michael R McClung, 2014, The New England journal of medicine.

Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries

A. Grauer, Yi Peng, R. Barron, 2016, Archives of Osteoporosis.

Clinical and Diagnostic Aspects of Medullary Thyroid Carcinoma Tumor Markers for the Medullary Thyroid Carcinoma

A. Grauer, E. Blind, 1992 .

Tumor markers for the medullary thyroid carcinoma.

A. Grauer, E. Blind, 1992, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study

P. Geusens, A. Grauer, J. Adachi, 2019, JBMR plus.

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

S. Cummings, C. Christiansen, I. Reid, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment

Jacques P. Brown, A. Grauer, R. Chapurlat, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Discussion: Newer bisphosphonates in the treatment of paget's disease of bone: Where we are and where we want to go

E. McCloskey, A. Grauer, S. Wallach, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Treatment of paget's disease of bone with the new bisphosphonate ibandronate (BM 21.0955) by intravenous injection and continuous infusion

A. Grauer, M. Seibel, R. Ziegler, 1995 .

Bisphosphonate in der Behandlung des Morbus Paget

A. Grauer, 2001 .

Changing concepts in the management of hereditary and sporadic medullary thyroid carcinoma.

A. Grauer, F. Raue, R. Gagel, 1990, Endocrinology and metabolism clinics of North America.

Clinical significance of antibodies against calcitonin.

A. Grauer, R. Ziegler, F. Raue, 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study

A. Grauer, J. Adachi, P. Ebeling, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Validation of the Osteoporosis-Specific Morisky Medication Adherence Scale in long-term users of bisphosphonates

T. N. Harrison, K. Reynolds, D. Gold, 2014, Quality of Life Research.

Psychometric Properties of the Osteoporosis-Specific Morisky Medication Adherence Scale in Postmenopausal Women with Osteoporosis Newly Treated with Bisphosphonates

T. N. Harrison, K. Reynolds, D. Gold, 2012, The Annals of pharmacotherapy.

Predictors of near-term fracture in osteoporotic women aged ≥65 years, based on data from the study of osteoporotic fractures

G. Oster, A. Grauer, J. Edelsberg, 2017, Osteoporosis International.

Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.

P. Kostenuik, A. Grauer, D. Dempster, 2012, Clinical therapeutics.

Effects of risedronate on fracture risk in postmenopausal women with osteopenia

A. Grauer, E. Siris, I. Barton, 2007, Osteoporosis International.

Determinants of imminent fracture risk in postmenopausal women with osteoporosis

G. Oster, A. Grauer, D. Weycker, 2020, Osteoporosis International.

Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States

M. Broder, A. Grauer, E. Lewiecki, 2019, JBMR plus.

Elevated Thrombomodulin Plasma Levels as a Result of Endothelial Involvement in Plasmodium falciparum Malaria

A. Grauer, R. Ziegler, A. Bierhaus, 1994, Thrombosis and Haemostasis.

Clinical Investigations Risedronate Rapidly Reduces the Risk for Nonvertebral Fractures in Women with Postmenopausal Osteoporosis

S. Boonen, A. Grauer, M. Brandi, 2004 .

Risedronate Rapidly Reduces the Risk for Nonvertebral Fractures in Women with Postmenopausal Osteoporosis

S. Boonen, A. Grauer, M. Brandi, 2004, Calcified Tissue International.

Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass

Klaus Engelke, Thomas Fuerst, Cesar Libanati, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures

S. Cummings, C. Christiansen, E. Vittinghoff, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

Jacques P. Brown, A. Grauer, C. Roux, 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome

A. Grauer, E. Lewiecki, S. Ferrari, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

J. Cauley, M. Bouxsein, D. Bauer, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Neutralizing antibodies against calcitonin.

A. Grauer, R. Ziegler, F. Raue, 1993, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off‐treatment biopsy study

Jacques P. Brown, A. Grauer, J. S. San Martin, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass

Jacques P. Brown, H. Genant, A. Grauer, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension

A. Grauer, R. Dinavahi, C. Libanati, 2019, Archives of Osteoporosis.

Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial

A. Grauer, R. Dinavahi, T. Hirama, 2019, Journal of Bone and Mineral Metabolism.

Denosumab for treatment of postmenopausal osteoporosis.

A. Grauer, D. Shechter, Mona M. Chitre, 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Five Years of Cenosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension

Jacques P. Brown, S. Cummings, E. Vittinghoff, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density

Graham M. Treece, A. Gee, A. Grauer, 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Five-year denosumab treatment of postmenopausalwomen with osteoporosis: results of the first twoyears of the freedom trial extension.

S. Cummings, J. Reginster, A. Grauer, 2011 .

OP0100 Superior Gains in Bone Mineral Density and Estimated Strength at The Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of The Phase 3 Open-Label Structure Study

A. Grauer, T. Keaveny, K. Engelke, 2016 .

[Therapy of hyperparathyroidism].

A. Grauer, F. Raue, 1994, Medizinische Klinik.

Role of voltage-dependent calcium channels in secretion of calcitonin from human medullary thyroid carcinoma cells

A. Grauer, H. Scherübl, H. Serve, 1989, Klinische Wochenschrift.

Diminished calcitonin secretion after ovariectomy without apparent reduction in calcitonin content in the rat.

A. Grauer, R. Ziegler, J. Silver, 1993, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Ibandronate treatment in Paget's disease of bone.

A. Grauer, R. Ziegler, R Ziegler, 1999, Bone.

Adrenal tumors provide insight into the role of cortisol in NK cell activity.

A. Grauer, M. Habra, A. Greenstein, 2021, Endocrine-related cancer.

Long-term efficacy of intravenous pamidronate in Paget's disease of bone.

A. Grauer, S. Scharla, B. Klar, 1994, Seminars in arthritis and rheumatism.

OP0251 Effects of 2 Years of Treatment with Romosozumab Followed by 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density

A. Díez-Pérez, A. Grauer, A. Chines, 2015 .

J. Cauley, M. Bouxsein, D. Bauer, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

S. Cummings, C. Christiansen, I. Reid, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass

Jacques P. Brown, H. Genant, A. Grauer, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.